Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. - Wikidata - wikimedia - TriplyDB

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

http://www.wikidata.org/entity/Q46117432

about

Recent advances in understanding and treating vasculitis Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Updates in ANCA-associated vasculitis The immunopathology of ANCA-associated vasculitis Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans.Efficacy of remission-induction regimens for ANCA-associated vasculitis.Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies.Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire Linking classification and therapeutic management of vasculitides.Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service.Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?New-generation therapy for ANCA-associated vasculitis.Impact of rituximab trials on the treatment of ANCA-associated vasculitis.B-cell-targeted therapy in adult glomerulonephritis.Treatment of ANCA-associated vasculitis.Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?Key advances in the clinical approach to ANCA-associated vasculitis.State of the art in the treatment of systemic vasculitides.Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long?Treatment of granulomatosis with polyangiitis (Wegener's).Biologic agents in the treatment of glomerulonephritides.

P2860

Q26747046-A526CE02-FB0E-40A3-AAA3-E65BC0571CB3 Q26751357-D1BA422C-C083-4AD5-8742-8C297F09ED07 Q26776308-1A9C9ADA-B727-4D37-BA01-7730E7A5D7A1 Q27025692-91C81125-76D9-419C-B73F-6470C9C7BE2F Q28069897-824C7E97-8043-4D7F-9AFF-F941D11D0659 Q28391531-AE2956FD-91F5-4EB2-B227-B7B762E98EA3 Q31150752-90A7238B-4771-4E84-BC7F-6E8E6E0512DE Q33683956-0BD24BC2-33F6-43A4-8A6B-B65BD166AB80 Q33706447-76EE8ABF-6B6B-4EE4-9D8A-03B535ECBD98 Q33757209-6123F655-D0EE-4CBE-A0BA-A280302128B9 Q33862188-643B4190-9D6A-429F-93E2-33A5B5C6EDDB Q34037683-E19DBDC8-E9A9-4720-B66B-C9E5CBEF0A76 Q34500502-BF3A57DD-F9F2-461C-980B-75CA43D92D29 Q34573847-D73AD766-B4B3-4415-8B63-83A2B536A830 Q35065425-65B2CF35-6E33-4704-9F64-E1C3B633D1D9 Q35212086-6F36DA95-4325-4EA5-8F51-A79BA1403752 Q35228543-1A5D6F99-0201-42A0-8788-EB5EBFAE3CA9 Q35426533-23CBB3DE-2145-4E3C-8FFA-6616EDE6266C Q35672892-4EDB3136-DFF6-4CB6-977C-4CF2A978B48F Q35759180-9E3C770F-C3AA-4B2F-ABF8-5D35EBE125D5 Q35777619-3A795C1F-6BB3-48CA-8517-986941A42232 Q35836369-4D0FEE23-4A69-4A7F-B2BA-6115274B6BCA Q35887318-55F9C5CE-7238-4496-88BC-3DCC06F92CB9 Q37031689-C7333BE0-21BD-4B34-9F30-EE713A78CC0C Q37282164-8C36C272-8A27-4E3C-9D1B-B5FF4CE35AC3 Q37640836-1C63BA32-905A-43E1-9B8F-A2F20318742B Q37682245-1B443BE1-DB34-495E-A24D-8981A841A909 Q37686029-747D86DB-3CFD-4108-AAEE-EBF422A85A41 Q38100780-532E048D-3CC7-4EDA-B9D0-9A81A7DB4BFF Q38113507-1D8213EE-508B-4F54-92AF-456E53AAFDFD Q38135271-BC09800D-9D3E-4BA6-B40A-1F8D1C5F769D Q38152651-9B09C4A5-C0BD-4E39-A58D-807407020C89 Q38159787-D623FADA-F1F3-42A0-B177-60D77B09AC4E Q38159916-8C0216FF-3137-4F34-97CE-2FDC3A4EB492 Q38204971-6ADE7F35-5C73-4043-B33D-D72C0372351B Q38224803-68D44C5E-C5FD-444F-B4E8-AE689E5022F7 Q38263514-5F61300A-6B9F-4922-9298-3AD31BFEF392 Q38327634-2788465A-5D64-4C07-87C1-401344BFD2AD Q38341601-5B564B8E-BF88-41CA-9F2A-17ECA289EF42 Q38514894-781DFB53-7069-4EB2-9EA6-DEBE32A42A40

P2860

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

http://www.wikidata.org/entity/Q46117432

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Rituximab for remission mainte ...... ntibody-associated vasculitis.

@en

Rituximab for remission mainte ...... ntibody-associated vasculitis.

@nl

type

label

Rituximab for remission mainte ...... ntibody-associated vasculitis.

@en

Rituximab for remission mainte ...... ntibody-associated vasculitis.

@nl

prefLabel

Rituximab for remission mainte ...... ntibody-associated vasculitis.

@en

Rituximab for remission mainte ...... ntibody-associated vasculitis.

@nl

P1433

Q46117432-CAA9A477-AB21-4950-B68D-4F1F5085CDB9

P1476

Q46117432-12E2FB13-6A3E-4E24-AE9F-B37F602E2B8A

P2093

Q46117432-1B98B01F-AEEE-492B-8FF4-28CFF32F1213

Q46117432-1CA9B550-80C5-4BD5-81C3-095AB9DE23E6

Q46117432-2F6B86B1-194A-40D6-B85A-01664D4F7A97

Q46117432-540C5B95-DB35-4C47-BA57-17F6312591D2

Q46117432-8609CC36-F16A-42B0-A1B5-78E2F61D03D0

Q46117432-C4C79597-01F4-4316-9ECF-1BB9EE6FD065

Q46117432-C8C2353A-C965-49C0-B7DE-D21A7C90856C

P2860

Q46117432-0DC2C601-D47F-4ED3-817D-C767C19A7063

Q46117432-0E23CA08-2A39-4B07-ABBD-434993D08B68

Q46117432-16E126DF-9ACA-4C7F-A409-E925AD31C8FA

Q46117432-4C00ECD4-28F2-47DD-802F-1257940EB9F9

Q46117432-50B496F0-F066-4911-A725-38D530EA1114

Q46117432-6C62D371-948F-4386-896D-6E4D4A4FC430

Q46117432-7500366E-0A37-466D-99A0-EB6E1765E193

Q46117432-7AD6A6B2-1000-4768-AD7B-98A64DF4383B

Q46117432-9470A0AC-16D0-4C86-938C-637047C7B99F

Q46117432-A7BC2199-E6A4-400D-825B-C4EB348A26F7

P304

Q46117432-3B1CD19D-52E5-49A5-8AC9-1BDD8D5AFC27

P31

Q46117432-B1C80D8C-450A-4360-9581-F1CF9FEFCD9F

P356

Q46117432-A61BCC52-4D43-472F-8076-F52A68840EB1

P433

Q46117432-93A1D138-4414-4403-AEA7-54703CCCDBE2

P478

Q46117432-D9BC07B5-BA7A-4EE2-8134-783D35CD8574

P50

Q46117432-C42547F7-F1F9-461E-A263-346C8C323174

P577

Q46117432-3B3EA0C0-1A7C-4EB0-B7BC-CD7D786B062A

P5875

Q46117432-C0A6C24C-7791-43B6-8E67-C1E2F55A655D

P698

Q46117432-38582C3B-51D2-4F64-BF2B-F80983E95BDD

P921

Q46117432-E4B646A8-7ED7-467D-8CF5-F2CF98E19C05

P356

P1433

Arthritis and Rheumatism

P1476

Rituximab for remission mainte ...... antibody-associated vasculitis

@en

P2093

Afzal Chaudhry

http://www.w3.org/2001/XMLSchema#string

David R W Jayne

http://www.w3.org/2001/XMLSchema#string

Fausta Catapano

http://www.w3.org/2001/XMLSchema#string

Kenneth G C Smith

http://www.w3.org/2001/XMLSchema#string

Mary-Jane Guerry

http://www.w3.org/2001/XMLSchema#string

Rona M Smith

http://www.w3.org/2001/XMLSchema#string

Simona Laurino

http://www.w3.org/2001/XMLSchema#string

P2860

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.

Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

EULAR recommendations for the management of primary small and medium vessel vasculitis.

P304

3760-3769

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.34583

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264355019

http://www.w3.org/2001/XMLSchema#string

P698

22729997

http://www.w3.org/2001/XMLSchema#string

P921